Baidu
map

Nat Commun:灵芝可调节肠道菌群改善肥胖

2015-07-01 佚名 生物谷

近日,来自台湾长庚大学的研究人员在国际学术期刊nature communication在线发表了一项最新研究进展,他们通过动物实验首次发现灵芝能够调节小鼠肠道菌群生态,改善肥胖。 肥胖已经逐渐成为全球性的公共健康问题,目前全世界大约有5亿肥胖的人和14亿体重超重的人。肥胖会促进许多并发症的发生,如糖尿病,心血管疾病,高血压和癌症,肥胖的发生主要是由于机体能量失衡所导致,能量摄入增加同时运

近日,来自台湾长庚大学的研究人员在国际学术期刊nature communication在线发表了一项最新研究进展,他们通过动物实验首次发现灵芝能够调节小鼠肠道菌群生态,改善肥胖。
 
肥胖已经逐渐成为全球性的公共健康问题,目前全世界大约有5亿肥胖的人和14亿体重超重的人。肥胖会促进许多并发症的发生,如糖尿病,心血管疾病,高血压和癌症,肥胖的发生主要是由于机体能量失衡所导致,能量摄入增加同时运动量减少是导致肥胖发生的主要原因。许多研究已经证明肥胖的发生常伴随慢性低度炎症以及肠道菌群生态紊乱,因此如何改善炎症,恢复肠道生态平衡成为肥胖研究的重要课题。
 
在这项研究中,研究人员从一种名贵中药--赤芝中提取出一种水提取物(WEGL),将其添加到高脂饮食诱导的肥胖小鼠食物中。赤芝是灵芝的一种,也是传统中医学中使用的一种中药材,在亚洲中药材中已经被使用了几个世纪,用于提高健康水平,同时也有研究推测其具有抗糖尿病效应。研究人员在对高脂诱导的肥胖小鼠进行了该药物处理之后发现这些肥胖小鼠表现出体重下降,炎症改善,胰岛素敏感性增加等获益表型,并且这些小鼠的肠道菌群生态紊乱也得到了逆转,除此之外,小肠屏障的完整度得以维持,还降低了代谢性内毒素血症的水平。
 
研究人员还通过粪便移植的方法将WEGL处理的小鼠的粪便转移到高脂饮食诱导的肥胖小鼠,也表现出抗肥胖,调节肠道菌群的作用。
 
总得来说,这项研究首次发现灵芝有降低体重调节肠道生态平衡的作用,这表明灵芝补品对于肥胖症和相关疾病的治疗也许会有用,但还需要进一步研究证明在人身上是否也有类似效应。

原始出处:

Chih-Jung Chang, Chuan-Sheng Lin, Chia-Chen Lu, Jan Martel, Yun-Fei Ko, David M. Ojcius, Shun-Fu Tseng, Tsung-Ru Wu, Yi-Yuan Margaret Chen, John D. Young & Hsin-Chih Lai.Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota.Nature Communications, June 23, 2015.doi:10.1038/ncomms8489

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (22)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2160723, encodeId=46682160e23f2, content=推测为主,缺乏具体实验数据,这也是发展不足的短板!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Tue Oct 03 10:08:19 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=78911, encodeId=abb0e89118d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78917, encodeId=6c0ce891789, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78916, encodeId=8d8de89167d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78915, encodeId=1cdbe89152c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78914, encodeId=9b5de891404, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78913, encodeId=15f9e8913a2, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78912, encodeId=362ce8912ba, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78910, encodeId=767fe891073, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78907, encodeId=fb7ae890730, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2023-10-03 jiazhoudexue 来自广东省

    推测为主,缺乏具体实验数据,这也是发展不足的短板!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2160723, encodeId=46682160e23f2, content=推测为主,缺乏具体实验数据,这也是发展不足的短板!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Tue Oct 03 10:08:19 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=78911, encodeId=abb0e89118d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78917, encodeId=6c0ce891789, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78916, encodeId=8d8de89167d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78915, encodeId=1cdbe89152c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78914, encodeId=9b5de891404, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78913, encodeId=15f9e8913a2, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78912, encodeId=362ce8912ba, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78910, encodeId=767fe891073, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78907, encodeId=fb7ae890730, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2160723, encodeId=46682160e23f2, content=推测为主,缺乏具体实验数据,这也是发展不足的短板!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Tue Oct 03 10:08:19 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=78911, encodeId=abb0e89118d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78917, encodeId=6c0ce891789, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78916, encodeId=8d8de89167d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78915, encodeId=1cdbe89152c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78914, encodeId=9b5de891404, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78913, encodeId=15f9e8913a2, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78912, encodeId=362ce8912ba, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78910, encodeId=767fe891073, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78907, encodeId=fb7ae890730, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2160723, encodeId=46682160e23f2, content=推测为主,缺乏具体实验数据,这也是发展不足的短板!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Tue Oct 03 10:08:19 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=78911, encodeId=abb0e89118d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78917, encodeId=6c0ce891789, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78916, encodeId=8d8de89167d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78915, encodeId=1cdbe89152c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78914, encodeId=9b5de891404, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78913, encodeId=15f9e8913a2, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78912, encodeId=362ce8912ba, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78910, encodeId=767fe891073, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78907, encodeId=fb7ae890730, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2160723, encodeId=46682160e23f2, content=推测为主,缺乏具体实验数据,这也是发展不足的短板!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Tue Oct 03 10:08:19 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=78911, encodeId=abb0e89118d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78917, encodeId=6c0ce891789, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78916, encodeId=8d8de89167d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78915, encodeId=1cdbe89152c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78914, encodeId=9b5de891404, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78913, encodeId=15f9e8913a2, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78912, encodeId=362ce8912ba, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78910, encodeId=767fe891073, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78907, encodeId=fb7ae890730, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2160723, encodeId=46682160e23f2, content=推测为主,缺乏具体实验数据,这也是发展不足的短板!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Tue Oct 03 10:08:19 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=78911, encodeId=abb0e89118d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78917, encodeId=6c0ce891789, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78916, encodeId=8d8de89167d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78915, encodeId=1cdbe89152c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78914, encodeId=9b5de891404, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78913, encodeId=15f9e8913a2, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78912, encodeId=362ce8912ba, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78910, encodeId=767fe891073, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78907, encodeId=fb7ae890730, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2160723, encodeId=46682160e23f2, content=推测为主,缺乏具体实验数据,这也是发展不足的短板!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Tue Oct 03 10:08:19 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=78911, encodeId=abb0e89118d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78917, encodeId=6c0ce891789, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78916, encodeId=8d8de89167d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78915, encodeId=1cdbe89152c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78914, encodeId=9b5de891404, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78913, encodeId=15f9e8913a2, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78912, encodeId=362ce8912ba, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78910, encodeId=767fe891073, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78907, encodeId=fb7ae890730, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2160723, encodeId=46682160e23f2, content=推测为主,缺乏具体实验数据,这也是发展不足的短板!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Tue Oct 03 10:08:19 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=78911, encodeId=abb0e89118d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78917, encodeId=6c0ce891789, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78916, encodeId=8d8de89167d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78915, encodeId=1cdbe89152c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78914, encodeId=9b5de891404, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78913, encodeId=15f9e8913a2, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78912, encodeId=362ce8912ba, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78910, encodeId=767fe891073, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78907, encodeId=fb7ae890730, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2160723, encodeId=46682160e23f2, content=推测为主,缺乏具体实验数据,这也是发展不足的短板!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Tue Oct 03 10:08:19 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=78911, encodeId=abb0e89118d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78917, encodeId=6c0ce891789, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78916, encodeId=8d8de89167d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78915, encodeId=1cdbe89152c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78914, encodeId=9b5de891404, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78913, encodeId=15f9e8913a2, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78912, encodeId=362ce8912ba, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78910, encodeId=767fe891073, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78907, encodeId=fb7ae890730, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2160723, encodeId=46682160e23f2, content=推测为主,缺乏具体实验数据,这也是发展不足的短板!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Tue Oct 03 10:08:19 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=78911, encodeId=abb0e89118d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78917, encodeId=6c0ce891789, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78916, encodeId=8d8de89167d, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78915, encodeId=1cdbe89152c, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78914, encodeId=9b5de891404, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78913, encodeId=15f9e8913a2, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78912, encodeId=362ce8912ba, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78910, encodeId=767fe891073, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78907, encodeId=fb7ae890730, content=发展传统医药事业, beContent=null, objectType=article, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 17 07:59:00 CST 2016, time=2016-04-17, status=1, ipAttribution=)]
    2016-04-17 忠诚向上

    发展传统医药事业

    0

相关资讯

Org Lett:灵芝和九香虫可能防治慢性肾病

中科院昆明植物研究所研究员程永现指导博士生晏永明发现,著名中药灵芝和九香虫可治疗慢性肾病。研究成果日前发表于《有机化学通讯》。 据介绍,慢性肾脏病在国内外的发病率已高达10%以上。该病较为隐匿,缺乏治疗药物,易进一步导致肾衰,进而使患者依赖于血液透析和肾脏移植。由于慢性肾脏病发病机制复杂,因此科研人员认为从中草药中寻找新的防治药物是可能的。 赤芝是中国药典收载的灵芝的一种,自古

Baidu
map
Baidu
map
Baidu
map